Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beyondspring Inc

2.79
-0.0400-1.41%
Post-market: 2.67-0.1200-4.30%17:58 EDT
Volume:106.95K
Turnover:290.22K
Market Cap:112.48M
PE:-32.72
High:2.85
Open:2.73
Low:2.64
Close:2.83
Loading ...

Press Release: BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting

Dow Jones
·
28 May

BeyondSpring Q1 EPS $(0.08) Down From $0.11 YoY

Benzinga
·
13 May

BeyondSpring Inc. Reports Q1 2025 Net Loss Increase by 24% with R&D Expenses Up 21%

Reuters
·
13 May

Press Release: BeyondSpring Reports First--Quarter 2025 Financial Results and Provides Corporate Update

Dow Jones
·
13 May

BeyondSpring reports FY24 EPS (21c) vs. (34c) last year

TIPRANKS
·
27 Mar

BeyondSpring Files 2024 Annual Report on Form 10-K

GlobeNewswire
·
27 Mar

Beyondspring FY Cash & Investments USD 2.9 Million

THOMSON REUTERS
·
27 Mar

Press Release: BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

Dow Jones
·
27 Mar

Beyondspring Announces $35.4 Million Sale of a Portion of Equity Interest in Seed Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

THOMSON REUTERS
·
28 Jan

Seed Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset Rbm39 Degrader and Enters Strategic Transactions With New Investors

THOMSON REUTERS
·
28 Jan

Seed Therapeutics- Expects Ind Filing for St-01156 in First Half of 2025

THOMSON REUTERS
·
28 Jan

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

GlobeNewswire
·
28 Jan

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

GlobeNewswire
·
28 Jan